Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)

Translated title of the contribution: Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)

die Multiple Sklerose Therapie Konsensus Gruppe (MSTKG)

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations

Abstract

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, Switzerland).

Translated title of the contributionMultiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)
Original languageGerman
Pages (from-to)773-801
Number of pages29
JournalNervenarzt
Volume92
Issue number8
DOIs
StatePublished - Aug 2021
Externally publishedYes

Keywords

  • Autoimmune-mediated disease
  • Early therapeutic intervention
  • Guideline
  • Immunotherapy
  • Treatment recommendation

Fingerprint

Dive into the research topics of 'Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)'. Together they form a unique fingerprint.

Cite this